Shares of Valeant Pharmaceuticals Intl Inc
VRX 4.55% were trading higher by more than 6 percent on Monday after the company
announced the Food and Drug Administration has accepted for review the Biologics License Application (BLA) the company submitted as part of a partnership with
AstraZeneca plc (ADR) AZN 0.22%.